Edward J. Dulac III, who serves as Executive Vice President and Chief Financial Officer for Intellia Therapeutics, Inc. (NASDAQ: NTLA), has completed a stock transaction resulting in proceeds of $84,186. According to a Form 4 filing recently submitted to the Securities and Exchange Commission, the executive sold 4,677 shares of the company's common stock on July 2, 2026. The shares were disposed of at a price of $18.00 per share, a figure that sits slightly above the current stock price of $17.87. This specific transaction was executed automatically pursuant to a 10b5-1 trading plan, which Mr. Dulac initially adopted on September 8, 2025. Following the completion of this sale, Mr. Dulac directly holds 156,286 shares of Intellia Therapeutics common stock.
The timing of this insider sale coincides with a period of significant appreciation for NTLA shares. The stock has surged 95% year-to-date and has climbed 80% over the past six months. According to InvestingPro analysis, the stock appears slightly undervalued at current levels based on Fair Value estimates. The platform identifies strong price momentum as one of 15 key ProTips available for NTLA, offering deeper insights for investors ahead of the company's earnings report scheduled for July 30.
In other recent developments, Intellia Therapeutics presented additional Phase 3 clinical trial results for its CRISPR gene editing treatment, lonvo-z, at the European Academy of Allergy & Clinical Immunology Annual Congress. The HAELO trial data, also published in the New England Journal of Medicine, showed an 89% reduction in the monthly rate of hereditary angioedema attacks requiring on-demand treatment compared to placebo. The treatment arm recorded a mean monthly rate of 0.19 attacks versus 1.79 in the placebo arm. Canaccord Genuity has reiterated a Buy rating with a $49.00 price target, while H.C. Wainwright also maintained a Buy rating with a $25.00 price target, both citing positive trial data. Citizens reiterated a Market Outperform rating with a $30.00 price target, following the additional data presented. These developments indicate continued confidence from analysts in Intellia's ongoing trials. Meanwhile, trading in options for Intellia Therapeutics saw a significant increase, with call volume reaching 6,365 contracts.
Intellia Therapeutics Inc closed at $17.87, up $0.31 or 1.77%. After hours trading showed the stock at $17.91, up $0.07 or 0.39%. The stock has shown strong performance over various timeframes, including 1D, 1W, 1M, 6M, 1Y, 5Y, and Max. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Is your NTLA trade worth the risk? Before you click buy, know exactly where to set your stop-loss. Our Vision AI literally sees your NTLA chart and delivers a complete risk management plan—entry, stop-loss, and profit target—in under 60 seconds. Protect your downside. Validate every trade. Invest smarter. July Sale - 60% Off InvestingPro